VivoSeq
Dermatology

Epidermolysis Bullosa

21

Pipeline Programs↗

10

Active Trials↗

16

Companies Involved↗

Epidermolysis Bullosa is an emerging landscape with 21 programs across 16 companies. The most active players are Castle Creek Pharmaceuticals, LLC, RegeneRx Biopharmaceuticals, Inc., InMed Pharmaceuticals Inc.. 7 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

15/100

Mech. Concentration

17/100

Completion Rate

67/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Castle Creek Pharmaceuticals, LLC

1 program

Phase 1R

RegeneRx Biopharmaceuticals, Inc.

1 program

Phase 2I

InMed Pharmaceuticals Inc.

1 program

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2V

Vyne Therapeutics Inc.

1 program

Phase 2P

Paradigm Therapeutics

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

28 of 29 classified programs — the dominant modality here.

3%ALL OTHERSGene therapy13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 36 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed16 · 44%
Terminated6 · 17%
Active, not recruiting4 · 11%
Recruiting4 · 11%
Unknown status2 · 6%
Withdrawn2 · 6%
Other2 · 6%

Clinical Trials

Trial Activity

36 trials

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Recruiting·XXinnate AB·Phase 2·NCT06594393·32 enrolled
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Recruiting·AAmryt Pharma·N/A·NCT06423573·580 enrolled
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Recruiting·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 3·NCT06917690·6 enrolled
Gentamicin for Junctional Epidermolysis Bullosa
Recruiting·UUniversity of Southern California·Phase 1/2·NCT03526159·6 enrolled
Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa
Active, not recruiting·FFundación DEBRA Chile, Niños Piel de Cristal·Phase 1·NCT06713434·20 enrolled
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
Active, not recruiting·RRHEACELL GmbH & Co. KG·Phase 3·NCT05838092·9 enrolled
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
Active, not recruiting·RRHEACELL GmbH & Co. KG·Phase 3·NCT05464381·91 enrolled
Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa
Active, not recruiting·—·Phase 1·NCT04171661·1 enrolled
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Not yet recruiting·PParadigm Therapeutics·Phase 3·NCT07482787·80 enrolled
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Not yet recruiting·PParadigm Therapeutics·Phase 3·NCT07482813·80 enrolled
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Completed·SScioderm, Inc.·Phase 2·NCT02014376·48 enrolled
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
Completed·SStanford University·Phase 2·NCT03836001·28 enrolled
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
Completed·—·Phase 2·NCT00951964·18 enrolled
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
Completed·IInMed Pharmaceuticals Inc.·Phase 2·NCT04908215·19 enrolled
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Completed·NNorthwestern University·Phase 2·NCT00825565·8 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)